Your search :

212 results

Changes within the Group Executive Committee
Changing the way we look at visible dermatoses
Pierre Fabre, 60 years of caring for everyone
1962-2022: the Pierre Fabre group celebrates its 60th anniversary
The SAFE study covered 7 countries and found that people are not paying proper attention to sun protection advice
Pierre Fabre Invest acquires a majority stake in the share capital of Ladrôme, a company specializing in organic natural health products
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology
Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (tab-cel®)